Events

Stay Informed with the Latest Political News on Politics Affairs

XTEP Debuts the 1st Mono Store in Malaysia with 160X Collection and Thousands of Local Runners Join XTEP Running Club

PUCHONG,Malaysia,Nov. 18,2024-- XTEP,a leading global sports brand,is proud to announce the grand opening of its first store in Malaysia,located at the IOI Shopping Mall in Puchong. The event,which to

Nov 19, 2024

Hang Seng Bank Unveils Newly Renovated Hong Kong Main Branch with the Debut of the Market-New 'Come to You' Service Concept

Applications of Innovative Technology and Environmental-friendly Designs HONG KONG,Nov. 18,2024-- HangSeng Bank (\'Hang Seng\') today (18 November 2024) unveiled the newly renovated Hong Kong Main Bra

Nov 19, 2024

Microland Recognized as a Leader for the Fifth Consecutive Year in the 2024 Gartner® Magic Quadrant™ for Managed Network Services

BENGALURU,India,Nov. 18,2024-- Microland is proud to announce its recognition as a Leader in the 2024 Gartner® Magic Quadrant™ for Managed Network Services (MNS) for the fifth consecutive year.

Nov 19, 2024

Japan's Sendai City to Show Video Clip Featuring Pro Figure Skater Yuzuru Hanyu at Taipei's Ximending Shopping District from November 25

- Showcasing Appeals of His Hometown,Sendai City - SENDAI,Japan,Nov. 18,2024-- As part of its visitor-attracting promotion,the City of Sendai in Miyagi Prefecture,northeastern Japan,will start airing

Nov 19, 2024

2024 World Cities Branding Conference convened in China's Macao

BEIJING,China,Nov. 18,2024-- The 2024 World Cities Branding Conference,with the theme "City is eternal creation",concluded on November 1 at the MGM COTAI. Representatives from international

Nov 19, 2024

VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

SHANGHAI and BOSTON,Nov. 18,2024-- VelaVigo Cayman Limited (VelaVigo),a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC),today anno

Nov 19, 2024

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Conver

78-Week results from Phase III randomized controlled trial (RCT) including switching data from reference denosumab to CT-P41 (biosimilar candidate of denosumab) demonstrate comparable efficacy and sa

Nov 19, 2024